NON-SMALL CELL LUNG CANCER

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) works better than osimertinib alone for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. About 587 adults with newly diagnosed or recurrent advanced lun…

This study tests a new drug called SKB264 against standard chemotherapy in about 376 people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy (EGFR-TKI). The goal is to see if SKB264 alone can he…

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This study tests whether adding stereotactic radiotherapy (precise radiation) to standard targeted therapy can better control brain metastases in people with non-small cell lung cancer. About 202 participants whose brain tumors did not fully shrink after 3-6 months of a third-gen…

This early-stage study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (breast, ovarian, lung, and others) that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor sh…

This early-stage study tests a new drug called YL202 in about 80 adults with advanced lung or breast cancer that has not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also measure how the body processes t…

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participan…

This early-phase study tests a new drug called AB248, either alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have spread. The main goals are to check safety and find the best dose. About 552 people with certain cancers like lung, melan…

This early-stage trial tests a precise, high-dose radiation therapy (SBRT) for people with non-small cell lung cancer located in the very center of the chest, near vital structures. The goal is to find the highest safe dose that limits severe side effects. About 30 participants w…

This study tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more tumor tissue in patients with advanced non-small cell lung cancer. About 90 participants will receive either chemo-immunotherapy or chemotherapy alone before their operation…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two rounds of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The goal is to see if this approach can control the cancer in the brain for…

This study tests whether adding hydroxychloroquine (a malaria drug) to the standard targeted therapy erlotinib can delay resistance in people with advanced non-small cell lung cancer that has specific EGFR mutations. About 76 participants received either erlotinib alone or erloti…

This study tests whether a new drug called sacituzumab govitecan works better than the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has spread and has not responded to previous treatments. About 600 participants will be randomly assigne…

This study tests a drug called DFMO combined with the immunotherapy pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). The goal is to find a safe dose and see if the combination helps shrink tumors. About 45 adults with measurable disease will take part.

This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has worsened after initial osimertinib treatment. About 98 participants will …

This study looks at people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). After 3 weeks on the targeted drug osimertinib, those who still have signs of the mutation in their blood are randomly assigned to either keep taking osimertinib a…

This study tests whether a combination of two targeted pills (encorafenib and binimetinib) can shrink tumors in Chinese patients with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer. About 63 adults who have not had prior BRAF or MEK inhibitor trea…

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that targets and attacks cancer cells, with the immunotherapy drug pemb…

This study tests whether adding a special type of radiotherapy to standard chemotherapy and immunotherapy before surgery can help people with stage III lung cancer that has spread to lymph nodes. The goal is to reduce the chance of cancer coming back. About 90 participants will r…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. Researchers use a simple blood test to find specific genetic changes in the cancer, then match patients to a treatment that targets those changes. The goal is to shrink …

This study tests whether the immunotherapy drug nivolumab, alone or with chemotherapy, can shrink early-stage non-small cell lung cancer before surgery and help prevent it from coming back after surgery. About 316 people with stage II or IIIA lung cancer that can be removed will …

This study offers continued treatment with lorlatinib for people with ALK-positive or ROS1-positive non-small cell lung cancer who are already benefiting from the drug in earlier Pfizer studies. The goal is to keep providing the medicine and monitor long-term safety. About 76 par…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This early-phase study tests whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer that has changes in the MET gene. The study includes about 3 adults with advanced lung cancer that cannot be removed by surgery. Researchers will monit…

This study tests whether adding a new drug (uliledlimab) to an immunotherapy (toripalimab) works better than standard immunotherapies alone for people with advanced non-small cell lung cancer that has certain markers (PD-L1 and CD73). About 450 adults who have not had treatment f…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This study tests whether adding two immunotherapy drugs (durvalumab and oleclumab) after standard chemoradiation can help control advanced lung cancer that cannot be removed by surgery. About 30 adults with stage III non-small cell lung cancer who have not gotten worse after chem…

This study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. The goal is to see if it can shrink tumors and control the disease safely. About 356 adults with specific genetic types of lung cance…

This early-stage trial tests a new daily pill, zongertinib, in adults with advanced cancers that have HER2 gene changes, including non-small cell lung cancer. The first part finds the safest dose; the second checks if it shrinks tumors. Participants stay on the drug as long as it…

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic cancer) that have a specific genetic mutation called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About…

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help control advanced non-small cell lung cancer. About 120 adults with stage IV lung cancer will receive either the combination or pembrolizumab alone. The goal is to see if the combination is safe a…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This study tests a new drug called BI-1910, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 35 adu…

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…

This study tests a new drug, JDQ443, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried platinum chemo and an immunotherapy. The goal is to see if…

This study tests whether adding radiation to a standard treatment of immunotherapy (pembrolizumab) plus chemotherapy can help people with advanced non-small cell lung cancer live longer. About 327 participants with stage IIIB or IV disease will receive the combination therapy. Th…

This early-phase study tests a new drug called HFB200603, either alone or with tislelizumab, in adults with advanced solid tumors (kidney, lung, skin, stomach, or colon cancer) that have not responded to prior treatments. The goal is to find a safe dose and check for side effects…

This study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This study tests two targeted drugs, encorafenib and binimetinib, in people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see how well the combination shrinks tumors and controls the disease. About 119 adults are taking part, and…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, for safety in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. About 41 participants will receive the drug to find the right dose and check for side …

This study tests a new drug, SHR-A2009, against standard chemotherapy in about 500 adults with advanced EGFR-mutant non-small cell lung cancer that worsened after EGFR-targeted pills. The goal is to see if SHR-A2009 can delay cancer growth better than chemo. Participants must hav…

This study is for people with small cell or non-small cell lung cancer whose disease has gotten worse after their first treatment. It tests a combination of three drugs: ADI-PEG 20, gemcitabine, and docetaxel. The goal is to find the safest dose and see if this mix can shrink or …

This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the combination could control the disease for at least 24 weeks. However, the study was withdrawn before …

This early-stage trial tests whether adding tepotinib to the immunotherapy pembrolizumab (Keytruda) can help treat advanced non-small cell lung cancer (NSCLC) that doesn't respond to immunotherapy alone. The study includes about 19 adults with NSCLC, some with a specific MET gene…

This study tests whether a shot under the skin (subcutaneous injection) of the immunotherapy drug pembrolizumab works as well as the standard IV infusion for people with advanced non-small cell lung cancer that has spread. About 67 participants will receive either the injection o…

This early-stage study tests a new drug called anvumetostat, alone or with other treatments, in adults with advanced chest cancers (like lung cancer) that have a specific missing gene (MTAP-deletion). The main goals are to find the safest dose and check for side effects. About 49…

This early-stage trial tests a new drug (AGEN1181) alone or with another drug (balstilimab) in people with advanced solid tumors that haven't responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 499 adults with …

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This study tested a new treatment plan for people with stage II or III non-small cell lung cancer. Participants first received precise radiation to the main tumor, then standard chemoradiation to the chest, followed by immunotherapy. The goal was to see if this approach could kee…

This study tests whether giving precise radiation to tumors that have just started to grow can delay the cancer from getting worse. It involves 107 adults with metastatic triple-negative breast cancer or non-small cell lung cancer. Participants are randomly assigned to receive ei…

This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer that has worsened after prior treatment with a similar drug. The goal is to see if adding two new drugs can shrink tumors or …

This study tests a new drug called JDQ443, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find safe doses and see if the drug shrinks tumors. About 74 adults with lung or colorectal cancer that has not …

This study tested whether adding the drug abemaciclib to standard care helps people with stage IV lung cancer that has a KRAS mutation live longer. All 453 participants had already tried chemotherapy. Half received abemaciclib plus supportive care, the other half received erlotin…

This study tests a combination of the drug tislelizumab plus other experimental drugs, with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combos can shrink tumors and control the disease. …

This study tests whether adding the experimental drug uliledlimab to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced…

This phase 3 study tests whether a new drug called ensartinib works better than the current standard drug crizotinib for people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer). About 290 patients who have had up to one prior chemotherapy but…

This study tests a new drug called divarasib against two existing drugs (sotorasib and adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C). About 338 participants who have already tried other treatments will be randomly assigned to receive divarasib or …

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is …

This early-phase study tests an experimental oral drug, HBI-2376, in 42 adults with advanced solid tumors (lung, colon, pancreatic, or other) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find the safest dose and unders…

This study tests whether adding a drug called savolitinib to the standard treatment osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified). About 30 adults whose cancer got worse on osi…

This study tests whether adding an investigational drug called fianlimab to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combination alone for people with advanced non-small cell lung cancer. About 950 adults who have not had prior treatment…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, and prostate cancer. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. About 702 adults w…

This study tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR mutation with MET amplification) live longer without their cancer growing. About 412 adults with incurable, advanced non-small cell lung ca…

This study tests whether adding the targeted drug alectinib to standard chemotherapy is safe for people with a specific type of lung cancer (ALK-positive non-small cell) after they have had surgery to remove the tumor. The 11 participants receive up to four cycles of the combinat…

This study tests whether adding chemotherapy (pemetrexed and carboplatin) to the targeted drug lazertinib can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer worsened while on lazertinib alone. About 87 adults will re…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that have …

This study tests whether adding thymosin alpha 1 to standard treatment helps people with advanced lung cancer complete a full year of immunotherapy after chemoradiation. About 114 adults with non-small cell lung cancer that cannot be surgically removed will participate. The goal …

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This study was designed to test a new drug called IN10018 combined with chemotherapy and an immunotherapy for people with advanced solid tumors, like lung cancer, that had stopped responding to prior treatments. The goal was to see if the combination could shrink tumors or slow t…

This study tests a new drug (SI-B001) combined with osimertinib in people with advanced non-small cell lung cancer that has stopped responding to earlier treatments. The goal is to see if the combination can shrink tumors or slow cancer growth. About 14 adults with specific genet…

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with a type of lung cancer called non-small cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were enrol…

This study tests a drug called taletrectinib in people with advanced lung cancer that has a specific change in the ROS1 gene. About 217 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to offer a new treatment option for this rare type of l…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants who have not received prior EGFR inhibitor treatment will take both drugs for up to 6 mont…

This study tests a new treatment plan for people with advanced lung cancer that cannot be removed by surgery. The plan uses a mix of chemotherapy and immunotherapy before and after radiation therapy. The goal is to see if this approach can help patients live longer without their …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in people with advanced solid tumors (like lung cancer) that have stopped responding to standard therapies. The main goal is to find the safest dose and understand side effects. About 60 parti…

This study tested an oral drug called selpercatinib in 857 people with advanced solid tumors that have a specific genetic change (RET). The goal was to find the best dose and see if the drug can shrink tumors. Participants had cancers like lung, thyroid, or colon that had stopped…

This study compares a new targeted drug (DZD9008) to standard chemotherapy in people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 324 participants who have not had prior treatment will be randomly assigned to receive either…

This study tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery helps keep the cancer from coming back. It involves 210 adults with stage IB to IIIA non-small cell lung cancer that was completely removed. Participants are randomly assigned to rece…

This early-stage trial tests an experimental drug called RC148 in 121 people with advanced non-small cell lung cancer that cannot be removed by surgery. The drug is given alone or with other treatments to see if it can shrink tumors or stop them from growing. The main goal is to …

This study tests whether a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated…

This study tests an experimental pill called BDTX-1535 for people with advanced non-small cell lung cancer or a type of brain tumor called glioblastoma. The drug targets specific genetic changes in the cancer cells. The goal is to see if it is safe and shrinks tumors. About 200 a…

This study tests whether a daily pill called osimertinib can stop early-stage lung cancer from returning after surgery. About 390 people with a specific gene mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either the drug or a placebo. The main goal is t…

This study tests whether two immunotherapy drugs, balstilimab and botensilimab, can safely control advanced non-small cell lung cancer. About 45 people who have not had prior treatment for metastatic disease will receive the combination. The main goal is to see how many patients …

This early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain genetic markers (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can …

This study tests whether a daily pill called osimertinib can keep lung cancer from coming back after surgery in people with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take the drug for up to 3 years. The main goal is to see ho…

This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already tried immunotherapy. The goal is to see if the triple therapy can shrink tumors and how safe it is. Participants mus…

This study tested whether adding the drug durvalumab to standard chemotherapy and radiation helps people with stage III lung cancer that cannot be removed by surgery. About 328 participants received either durvalumab or a placebo alongside their cancer treatment. The main goal wa…

This study tests the safety of adding an experimental drug (MPDL3280A) to standard chemotherapy and radiation for people with non-small cell lung cancer that cannot be removed by surgery. About 52 participants will receive the combination therapy at MD Anderson Cancer Center. The…

This study tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose cancer worsened after initial targeted therapy (EGFR-TKI). The goal is to see if the new drug can slow cancer growth and improve survival. Partic…

This study tests a precise type of radiation (SABR) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. About 39 participa…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participants will …

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better …

This study tests an experimental drug called PF-06801591 that helps the immune system fight cancer. It is for people with advanced solid tumors or non-small-cell lung cancer that has not responded to other treatments. The study has two parts: one to find the right dose and check …

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard therapies. The goal is to find the best dose and see if the drug can shrink tumors. About 1,410 participants will receive the …

This study tests a new drug, BT5528, alone or with another drug (nivolumab) in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The main goals are to find saf…

This study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors.…

This study tests a drug called T-DXd (Enhertu) in 27 people with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung cancers,…

This study tests a new drug called BL-B01D1, given alone or with another drug (osimertinib), in people with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and how safe it is. About 198 adults with this type of lung cancer will take part.

This study tests an experimental drug called AB-106 in 173 adults with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive AB-106 alone, and thei…

This study is for people with certain lung, liver, or head/neck cancers that can be removed with surgery. Participants receive an investigational drug called cemiplimab, sometimes combined with another drug called fianlimab, before their operation. The goal is to see if these dru…

This study tests whether the drug atezolizumab can help prevent non-small cell lung cancer from coming back after surgery and chemotherapy. About 1,280 people with stage IB to IIIA lung cancer took part. Half received atezolizumab for about a year, and half received standard moni…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors or slow disease in people with advanced EGFR-mutant non-small cell lung cancer who have not yet taken EGFR inhibitors. About 25 participants will receive the combination and be m…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This study looks at whether having a cancer survivor's regular doctor work closely with their cancer team can help manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers (like breast, prostate, or lung) and at …

This study tests a drug called entrectinib in people with advanced cancers that have certain gene changes (NTRK, ROS1, or ALK). About 534 adults with 15 different cancer types will take the pill daily. The goal is to see if the drug shrinks tumors and how long that effect lasts.

This early-phase study tests an experimental drug called KIN-2787 in adults with advanced solid tumors (including lung cancer and melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the best dose, and see if the drug can shrink tumor…

This study tests a new approach for people with stage IV non-small cell lung cancer that has spread to only a few other places (oligometastatic). Participants receive immunotherapy and chemotherapy, plus precise radiation to the metastases, followed by surgery or radiation to the…

This study tests two treatments for people with advanced ALK-positive non-small cell lung cancer who haven't had treatment yet. One group gets the targeted drug brigatinib alone, and the other gets brigatinib plus chemotherapy. The goal is to see if the combination helps keep the…

This early-stage study tests a new drug called MK-2870, alone or with other cancer treatments, in 30 Japanese adults with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. This is not a cure, but aims to control the disease.

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not received prior treatment for their advanced cancer. The goal is to see if the drug helps them live longer and co…

This study tests a new combination treatment for people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The treatment uses a modified virus (VSV-IFNβ-NIS) plus an immunotherapy drug (pembrolizumab) to help the immune sys…

This study tests whether the targeted drug selpercatinib works better than standard chemotherapy for people with a rare type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). About 261 participants will receive either selpercatinib or standard treatment. T…

This study tests whether combining three drugs—nivolumab, ipilimumab, and nintedanib—can shrink tumors in people with advanced non-small cell lung cancer that cannot be cured. About 66 adults with no other treatment options will take part. The goal is to find the safest dose and …

This study tests two experimental drug combinations (durvalumab plus oleclumab or monalizumab) in adults with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The goal is to se…

This study tests a new drug, ARRY-614, combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks if the comb…

This study tests whether giving the immunotherapy drug durvalumab together with standard chemotherapy before surgery or radiation can help people with stage IIB to IIIB non-small cell lung cancer. Participants first receive the drug combination, then either have surgery followed …

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests whether giving the targeted drug osimertinib, alone or with chemotherapy, before surgery can shrink tumors more than chemotherapy alone in people with a specific genetic mutation (EGFR) in early-stage lung cancer. About 358 adults with resectable non-small cell l…

This study is for people with stage 1B to 3A non-small cell lung cancer who will have surgery. Participants receive chemotherapy and an immunotherapy drug (cemiplimab) with or without a cholesterol-lowering drug (alirocumab) before surgery. The goal is to see if adding alirocumab…

This study compares a new drug, BL-B01D1, to the standard chemo docetaxel in people with advanced non-small cell lung cancer that has not responded to previous treatments. About 698 adults whose cancer has spread or cannot be removed will take part. The goal is to see if BL-B01D1…

This study tests a combination of two drugs (tuvusertib and cemiplimab) in people with a type of advanced lung cancer that has stopped responding to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. About 61 participants will take p…

This study tests a combination of two drugs, ensartinib and bevacizumab, in people with a specific type of advanced lung cancer that has changes in the ALK and TP53 genes. The goal is to see if this combination can keep the cancer from growing for longer. The study includes 47 ad…

This study tests whether adding ramucirumab to the standard drug osimertinib can better control advanced EGFR-mutant lung cancer. About 160 people with non-squamous non-small cell lung cancer that cannot be surgically removed will be randomly assigned to receive either the combin…

This study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…

This study tested whether adding tepotinib to the standard drug osimertinib can help people with advanced non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The trial included 140 adults whose tumors had a specific genetic change (MET amplificati…

This early-stage study tested a new drug called amivantamab, alone or with other treatments, in over 750 people with advanced non-small cell lung cancer. The goal was to find safe doses and see if the drug could shrink tumors or slow the disease. Participants had already tried st…

This program provides early access to the drug capmatinib for people with advanced non-small cell lung cancer who have run out of standard treatments. It is only available when a doctor requests it for a patient who cannot join a clinical trial. The goal is to offer a potential t…

This study tests a pill called sunvozertinib given before surgery to people with a certain type of lung cancer (stage II-IIIB non-small cell lung cancer with EGFR exon 20 insertion mutations). The goal is to see if the drug can shrink tumors and improve surgical outcomes. About 2…

This study tests a new drug called BL-M02D1 in people with advanced solid tumors, including non-small cell lung cancer that has stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 14 adults are taking part in this ea…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or placebo plus chemo, f…

This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…

This study looks at whether adding a special type of radiation (SABR) to standard cancer therapy can help people with non-small cell lung cancer that has spread to only a few spots in the body. About 140 adults will be randomly assigned to get either standard treatment alone or s…

This study tests a combination of two drugs, alectinib and cobimetinib, in people with advanced ALK-positive non-small cell lung cancer. The goal is to find the highest safe dose and see how well the drugs shrink tumors. About 16 adults with this specific genetic type of lung can…

This study tests whether combining the drug durvalumab with radiation therapy can delay cancer worsening in people with stage II or III non-small cell lung cancer, without using chemotherapy. About 61 adults with newly diagnosed or recurrent cancer will receive the treatment. The…

This early-phase trial tests a treatment for people with advanced solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. The approach uses a person's own white blood cells, which are modified in a lab to better recognize and attack…

This study tests whether a single, high-precision radiation treatment (SBRT) is as safe and effective as multiple doses for people with central non-small cell lung cancer. About 30 participants with early-stage tumors will receive one targeted radiation session. Researchers will …

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) in a single shot. It enrolls 18 adults with various advanced solid tumors that have spread or come back. The main goal is to find the safest dose and underst…

This early-stage study tests an oral drug called Mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 participants will take the drug daily for up to a year or longer…

This study tests whether adding a new immunotherapy drug, relatlimab, to the standard nivolumab-plus-chemotherapy treatment helps shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 adults with stage IV or recurrent disease will receive…

This study tests a combination of two immunotherapy drugs (zimberelimab and domvanalimab) as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combo helps control the cancer longer than …

This early-stage trial tests a new drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. Researchers will also check if the drug can shrin…

This study tests a new combination of immune-boosting drugs for people with advanced solid tumors (like lung, bladder, or skin cancer) whose cancer stopped responding to standard immunotherapy. About 40 participants will receive a novel drug called NAI along with other therapies …

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find safe doses and check for side effects. About 72 participants will receive increa…

This study is testing a new drug called DZD9008 in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes and has stopped responding to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it …

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (lung, kidney, head and neck, colorectal, pancreatic, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study tested a combination of two drugs, nivolumab and ramucirumab, in 36 adults with advanced non-small cell lung cancer that had come back or spread. All participants had already received immunotherapy. The main goal was to see if the combination could control the disease …

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior tr…

This study tests whether giving extra radiation to the most active parts of a lung tumor can reduce the chance of cancer returning in the chest. About 78 adults with locally advanced non-small cell lung cancer will either receive standard chemoradiotherapy or standard treatment p…

This study tests a new experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and to see if the combin…

This study tests a two-step treatment approach for people with a specific type of lung cancer (EGFR-mutant, stages II to IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments,…

This study tests an experimental drug, zelenectide pevedotin, in people with advanced non-small cell lung cancer that has a specific genetic change called NECTIN4 amplification. Participants must have already tried at least one prior cancer treatment. The goal is to see if the dr…

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …

This study tests whether adding chemotherapy to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced non-small-cell lung cancer that has high levels of PDL1 (a protein that helps tumors hide). About 349 adults who have not had prior …

This study looks at whether a liquid biopsy (a blood test) can help doctors decide on treatment faster for people with advanced non-small cell lung cancer. Currently, patients often wait for results from a tissue biopsy, which can take weeks. The study will compare how quickly tr…

This study tests whether giving trilaciclib before chemotherapy can prevent bone marrow suppression in people with advanced non-small cell lung cancer. About 41 participants will receive the drug before their standard platinum-based chemo. The main goal is to see if it reduces se…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This study looks at two ways to give radiation to brain tumors in people with cancers like lung, breast, kidney, or melanoma who are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the standard on…

This study looks at whether people with certain cancers (lung, kidney, or skin) prefer getting pembrolizumab as a shot under the skin instead of through an IV. About 147 participants will try both methods and then say which they like better. The goal is to see if the shot is more…

This study looks at whether eating fermented foods (like yogurt, kimchi, and sauerkraut) can help people with rectal or lung cancer respond better to their standard treatments. About 39 patients will either add these foods to their diet or continue eating normally. Researchers wi…

This study tests a new support program for adults with lung cancer or mesothelioma who have finished treatment. The goal is to help them improve their quality of life as they move from active treatment to regular check-ups. About 21 participants will try the program to see if it …

This study tests whether adding acupuncture to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. About 60 participants will receive either real or sham acupuncture alongside their first four treatment cycles. The goal is to see if a…

This study looks at the bacteria living in the lungs, airways, and gut of 40 people with non-small cell lung cancer. Half of the participants have surgery only, while the other half also receive chemotherapy. The goal is to understand how these bacteria change and relate to each …

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study collects and analyzes tumor samples from over 3000 adults with advanced cancers like breast, lung, and colorectal cancer. The goal is to identify specific biomarkers in each person's cancer that can help doctors choose the most suitable targeted therapy or clinical tri…

This study looks at how the heart works during a 6-minute walk test in people with advanced lung cancer who are getting chemotherapy, radiation, and immunotherapy. The goal is to see if heart measurements can help predict side effects and survival. About 231 adults with untreated…

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced lung cancer compared to usual care. About 659 participants with stage IIb-IV non-small cell lung cancer will be followed to see if the expert approach…

This study looks at people with suspected or confirmed non-small cell lung cancer who need a tissue sample for genetic testing. It compares taking 2 versus 3 samples from each lymph node during an ultrasound-guided biopsy to see which method gives enough material for testing. It …

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study gives the immunotherapy drug durvalumab to people with operable non-small cell lung cancer before their surgery. The main goal is to see how the drug changes the tumor and immune system, not to cure the disease. About 25 adults with stage IIA to IIIB lung cancer will t…

This study follows about 5,000 people with non-small cell lung cancer to see how doctors use the VeriStrat blood test when deciding on treatment. Researchers want to learn if the test helps pick better therapies and improves patient outcomes. No new treatment is given; the study …

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study looks at how detailed analysis of PET/CT scans, combined with artificial intelligence, can help doctors better understand non-small cell lung cancer. Researchers will use data from 500 patients to build models that predict cancer stage, genetic changes, and patient out…

This study looks at how small genetic differences (called SNPs) in lung cancer patients might influence how well the drug alectinib works and what side effects it causes. Researchers will analyze DNA from 600 people with ALK-positive non-small cell lung cancer who have been takin…

This study compares two types of minimally invasive lung cancer surgery: robotic-assisted and video-assisted (VATS). The goal is to see which one leads to better quality of life and lower costs for patients with early-stage lung cancer. About 446 adults took part, and researchers…

This study looks at whether PET-CT scans can accurately predict if non-small cell lung cancer has spread to nearby lymph nodes. Researchers will compare scan results with actual tissue samples from surgery in 280 patients. The goal is to see if scans alone can guide treatment dec…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…

This study follows up to 400 people who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The goal is to track long-term side effects and see how well the treatment effects last over time. No new treatment is given—par…

This study looks at a DNA repair issue called homologous recombination deficiency (HRD) in people with a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers want to find out how common HRD is and whether it affects how the cancer behaves or responds to treatmen…

This study screens up to 1,150 adults with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers collect blood or tissue samples to check for specific genetic markers and tumor proteins. The goal is to identify patients who might be eligible for future t…

This study compares two common treatments for stage I non-small cell lung cancer: surgery and stereotactic body radiation therapy (SBRT). About 446 patients will report their quality of life and symptoms for up to 3 years after treatment. The goal is to see which approach offers …

This study looks at whether a blood test that detects tumor DNA can help doctors decide when to stop immunotherapy in people with advanced melanoma or lung cancer. About 39 adults who have been on immunotherapy for at least a year and show good response will be followed. The goal…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study aims to collect medical history and tissue or saliva samples from 100 people with a specific type of advanced lung cancer called ALK+ non-small cell lung cancer. Researchers will analyze these samples to better understand the genetic and immune features of the disease.…

This study collects and analyzes lung cancer tissue samples from 500 patients in Asia to find out which genetic changes are most common. The goal is to better understand the disease in the local population. Participants must have a tissue sample available and be healthy enough fo…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study looks at how well the cancer drug atezolizumab works when used in regular hospitals and clinics, not just in strict research settings. It includes over 2,700 people with bladder, lung, or liver cancer. The goal is to see how long patients live and how safe the drug is …

This study looks at how doctors in Russia treat advanced or metastatic non-small-cell lung cancer in everyday practice. Researchers will follow about 1500 adults across 20 cancer centers to see which treatments and genetic tests are used. The goal is to understand real-world care…

This study looks back at 46 adults with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers want to see which treatment strategies worked best by tracking how long patients stayed free of cancer growth. The goal is to find a standard app…

This study compares a new lab technique called OSNA with standard methods to detect tiny cancer deposits in lymph nodes of people with early-stage lung cancer. About 130 participants will have their lymph nodes analyzed after robotic lung surgery. The goal is to see if OSNA can f…

This pilot study is testing whether changes in tumor DNA found in the blood can help doctors see if immunotherapy is working in patients with non-small cell lung cancer or kidney cancer. About 100 adults will give blood samples before and during their standard treatment. The goal…